1.50 CME Credit
A Pri-Med Curriculum - Incretin-Based Multiagonist Therapy: Emerging Treatment for Diabetes and Obesity
Do you care for patients with diabesity (type 2 diabetes and obesity) and want to better understand how incretin hormone targeting medications like GLP-1 receptor agonists have revolutionized the treatment of these conditions? Are you interested in the emerging data around incretin multiagonists and how they may further extend the benefits of GLP-1 receptor agonists provide in this patient population?
If so, take part in this self-paced curriculum that reviews the physiology behind incretin-based agonists and discusses their current and rapidly expanding role in the care of people with type 2 diabetes and obesity.Take this 3-part series of short interactive video modules that are broken down by topic and go into more detail on each learning objective. Earn a maximum of 1.50 AMA credits by completing all 3 activities!
- Discuss the interrelationship between T2DM and obesity and the therapeutic advantages of early treatment intensification to reduce the long-term health risks associated with both conditions.
- Explore incretin physiology to understand the clinical benefits of incretin-based therapies on glycemic control, weight, and other metabolic processes.
- Evaluate clinical trial evidence that demonstrates the value of incretin-based multireceptor agonism in the future care of patients with T2DM, obesity, and related metabolic disorders.
1.50 CME/CE CREDITS
0.40 AANP | 0.04 PHARMACOLOGY
0.42 AANP | 0.42 PHARMACOLOGY
0.58 AANP | 0.58 PHARMACOLOGY
Jennifer B. Green, MD
Professor of Medicine
Department of Medicine, Division of Endocrinology
Faculty Member, Duke Clinical Research Institute
Duke University Medical Center
Robert F. Kushner, MD, FACP
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Supporters and Partners
Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com